Aprea AB - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 22 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Aprea AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Aprea AB - Product Pipeline Review - 2014', provides an overview of the Aprea AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aprea AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Aprea AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Aprea AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Aprea AB's pipeline products

Reasons to buy

- Evaluate Aprea AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Aprea AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Aprea AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Aprea AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aprea AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Aprea AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Aprea AB Snapshot 4
Aprea AB Overview 4
Key Information 4
Key Facts 4
Aprea AB - Research and Development Overview 5
Key Therapeutic Areas 5
Aprea AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Aprea AB - Pipeline Products Glance 9
Aprea AB - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Aprea AB - Early Stage Pipeline Products 10
Discovery Products/Combination Treatment Modalities 10
Aprea AB - Drug Profiles 11
APR-246 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
APR-017 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
APR-246 Analogues 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Aprea AB - Pipeline Analysis 14
Aprea AB - Pipeline Products by Target 14
Aprea AB - Pipeline Products by Route of Administration 15
Aprea AB - Pipeline Products by Molecule Type 16
Aprea AB - Pipeline Products by Mechanism of Action 17
Aprea AB - Recent Pipeline Updates 18
Aprea AB - Dormant Projects 19
Aprea AB - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables
Aprea AB, Key Information 4
Aprea AB, Key Facts 4
Aprea AB - Pipeline by Indication, 2014 6
Aprea AB - Pipeline by Stage of Development, 2014 7
Aprea AB - Monotherapy Products in Pipeline, 2014 8
Aprea AB - Phase I, 2014 9
Aprea AB - Discovery, 2014 10
Aprea AB - Pipeline by Target, 2014 14
Aprea AB - Pipeline by Route of Administration, 2014 15
Aprea AB - Pipeline by Molecule Type, 2014 16
Aprea AB - Pipeline Products by Mechanism of Action, 2014 17
Aprea AB - Recent Pipeline Updates, 2014 18
Aprea AB - Dormant Developmental Projects,2014 19